Prime Med­i­cine is head­ed for the clin­ic af­ter win­ning a dis­pute with Beam Ther­a­peu­tics, an­oth­er gene edit­ing biotech with roots in the same lab.

Ar­bi­tra­tors...

The Trump ad­min­is­tra­tion is push­ing the FDA to ce­ment the de­tails be­hind its proac­tive pub­lic re­lease of re­jec­tion let­ters sent to phar­ma com­pa­nies. The push...

Two weeks af­ter the Eu­ro­pean Com­mis­sion launched an in­ves­ti­ga­tion in­to Sanofi, the French drug­mak­er has of­fered to stop mak­ing neg­a­tive claims about a ri­val drug­mak­er's...

Plus news about Seres, Bio­cy­to­gen, White­hawk, Boehringer In­gel­heim, Prime Vec­tor and Min­dRank.

⚠️ No­var­tis re­duces New Jer­sey head­count: A WARN no­ticefor the state notes...

They say that the way to make mon­ey in a gold rush is to open a shop sell­ing picks and shov­els. By the same to­ken...